首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis.
【24h】

Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis.

机译:甲状腺乳头状癌的基因表达谱鉴定出与BRAF突变状态和淋巴结转移相关的转录本。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To identify papillary thyroid carcinoma (PTC)-associated transcripts, we compared the gene expression profiles of three Serial Analysis of Gene Expression libraries generated from thyroid tumors and a normal thyroid tissue. EXPERIMENTAL DESIGN: Selected transcripts were validated in a panel of 57 thyroid tumors using quantitative PCR (qPCR). An independent set of 71 paraffin-embedded sections was used for validation using immunohistochemical analysis. To determine if PTC-associated gene expression could predict lymph node involvement, a separate cohort of 130 primary PTC (54 metastatic and 76 nonmetastatic) was investigated. The BRAF(V600E) mutational status was compared with qPCR data to identify genes that might be regulated by abnormal BRAF/MEK/extracellular signal-regulated kinase signaling. RESULTS: We identified and validated new PTC-associated transcripts. Three genes (CST6, CXCL14, and DHRS3) are strongly associated with PTC. Immunohistochemical analysis of CXCL14 confirmed the qPCR data and showed protein expression in PTC epithelial cells. We also observed that CST6, CXCL14, DHRS3, and SPP1 were associated with PTC lymph node metastasis, with CST6, CXCL14, and SPP1 being positively correlated with metastasis and DHRS3 being negatively correlated. Finally, we found a strong correlation between CST6 and CXCL14 expression and BRAF(V600E) mutational status, suggesting that these genes may be induced subsequently to BRAF activation and therefore may be downstream in the BRAF/MEK/extracellular signal-regulated kinase signaling pathway. CONCLUSION: CST6, CXCL14, DHRS3, and SPP1 may play a role in PTC pathogenesis and progression and are possible molecular targets for PTC therapy.
机译:目的:为鉴定乳头状甲状腺癌(PTC)相关的转录本,我们比较了从甲状腺肿瘤和正常甲状腺组织产生的三个基因表达文库的系列分析的基因表达谱。实验设计:使用定量PCR(qPCR)在一组57个甲状腺肿瘤中验证所选的转录本。使用免疫组织化学分析,将一组独立的71个石蜡包埋切片用于验证。为了确定PTC相关基因表达是否可以预测淋巴结受累,研究了130个原发性PTC(54个转移性和76个非转移性)的单独队列。将BRAF(V600E)突变状态与qPCR数据进行比较,以鉴定可能受到异常BRAF / MEK /细胞外信号调节激酶信号转导调控的基因。结果:我们确定并验证了与PTC相关的新成绩单。三种基因(CST6,CXCL14和DHRS3)与PTC密切相关。 CXCL14的免疫组织化学分析证实了qPCR数据,并显示了PTC上皮细胞中的蛋白表达。我们还观察到CST6,CXCL14,DHRS3和SPP1与PTC淋巴结转移相关,而CST6,CXCL14和SPP1与转移呈正相关,而DHRS3则呈负相关。最后,我们发现CST6和CXCL14表达与BRAF(V600E)突变状态之间存在很强的相关性,表明这些基因可能在BRAF激活后被诱导,因此可能位于BRAF / MEK /细胞外信号调节激酶信号通路的下游。结论:CST6,CXCL14,DHRS3和SPP1可能在PTC的发生和发展中起作用,并且可能是PTC治疗的分子靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号